Latest news with #ProQRTherapeutics
Yahoo
5 days ago
- Business
- Yahoo
ProQR Therapeutics Second Quarter 2025 Earnings: Misses Expectations
Explore ProQR Therapeutics's Fair Values from the Community and select yours ProQR Therapeutics (NASDAQ:PRQR) Second Quarter 2025 Results Key Financial Results Revenue: €3.98m (down 39% from 2Q 2024). Net loss: €12.2m (loss widened by 352% from 2Q 2024). €0.12 loss per share (further deteriorated from €0.033 loss in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period ProQR Therapeutics Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 7.7%. Earnings per share (EPS) also missed analyst estimates by 50%. Looking ahead, revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are up 4.3% from a week ago. Risk Analysis Before you take the next step you should know about the 2 warning signs for ProQR Therapeutics that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
01-05-2025
- Business
- Yahoo
ProQR Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of ProQR Therapeutics (PRQR) with an Outperform rating and $5 price target ProQR represents a 'true' biotech investment given its early-stage, emerging technology with 'a plethora of potential applications,' ovel first in class targets and a wide array of strategic optionality for the company, but over the last few years investors have increasingly focused on derisked targets and indications, which is why the stock is trading at cash despite what the firm calls 'significant internal progress' and external validation. Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on PRQR: Disclaimer & DisclosureReport an Issue ProQR Announces New CFO and CMO to Drive Growth ProQR Therapeutics appoints Hom as CFO, Lopez as CMO ProQR Therapeutics Advances RNA Editing Pipeline ProQR's Axiomer Technology and AX-0810: A Promising Buy Rating with Increased Price Target ProQR Therapeutics price target raised to $12 from $10 at H.C. Wainwright Sign in to access your portfolio
Yahoo
29-04-2025
- Business
- Yahoo
ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse assumed coverage of ProQR Therapeutics (PRQR) with an Overweight rating and $8 price target ProQR is a leader in RNA editing and the initial biomarker data for its first program targeting bile acid transporter in Q4 will be an 'important catalyst,' the analyst tells investors in a research note. Cantor views the company as a 'pure play' on RNA editing. Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on PRQR: Disclaimer & DisclosureReport an Issue ProQR Therapeutics initiated with an Outperform at Evercore ISI ProQR Announces New CFO and CMO to Drive Growth ProQR Therapeutics appoints Hom as CFO, Lopez as CMO ProQR Therapeutics Advances RNA Editing Pipeline ProQR's Axiomer Technology and AX-0810: A Promising Buy Rating with Increased Price Target
Yahoo
14-03-2025
- Business
- Yahoo
ProQR Therapeutics Full Year 2024 Earnings: Misses Expectations
Revenue: €19.5m (up 196% from FY 2023). Net loss: €27.8m (loss narrowed by 1.3% from FY 2023). €0.32 loss per share (improved from €0.35 loss in FY 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) also missed analyst estimates by 7.3%. Looking ahead, revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 10% from a week ago. Before you take the next step you should know about the 3 warning signs for ProQR Therapeutics that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
